ACUT
Price
$0.24
Change
-$0.00 (-0.00%)
Updated
Dec 17 closing price
BLTE
Price
$62.96
Change
-$0.10 (-0.16%)
Updated
Dec 18 closing price
99 days until earnings call
Ad is loading...

ACUT vs BLTE

Header iconACUT vs BLTE Comparison
Open Charts ACUT vs BLTEBanner chart's image
Accustem Sciences
Price$0.24
Change-$0.00 (-0.00%)
Volume$323
CapitalizationN/A
Belite Bio
Price$62.96
Change-$0.10 (-0.16%)
Volume$36.36K
CapitalizationN/A
ACUT vs BLTE Comparison Chart
Loading...
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BLTE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACUT vs. BLTE commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACUT is a Hold and BLTE is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (ACUT: $0.24 vs. BLTE: $62.96)
Brand notoriety: ACUT and BLTE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACUT: 9% vs. BLTE: 44%
Market capitalization -- ACUT: $2.75M vs. BLTE: $1.94B
ACUT [@Biotechnology] is valued at $2.75M. BLTE’s [@Biotechnology] market capitalization is $1.94B. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACUT’s FA Score shows that 1 FA rating(s) are green whileBLTE’s FA Score has 0 green FA rating(s).

  • ACUT’s FA Score: 1 green, 4 red.
  • BLTE’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACUT and BLTE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACUT’s TA Score shows that 3 TA indicator(s) are bullish while BLTE’s TA Score has 4 bullish TA indicator(s).

  • ACUT’s TA Score: 3 bullish, 5 bearish.
  • BLTE’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both ACUT and BLTE are a bad buy in the short-term.

Price Growth

ACUT (@Biotechnology) experienced а +0.04% price change this week, while BLTE (@Biotechnology) price change was -1.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.11%. For the same industry, the average monthly price growth was -2.34%, and the average quarterly price growth was +0.25%.

Reported Earning Dates

BLTE is expected to report earnings on Mar 28, 2025.

Industries' Descriptions

@Biotechnology (-7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BLTE($1.94B) has a higher market cap than ACUT($2.75M). BLTE YTD gains are higher at: 37.617 vs. ACUT (-61.307). ACUT has higher annual earnings (EBITDA): -1.74M vs. BLTE (-35.42M). ACUT (0) and BLTE (0) have equivalent revenues.
ACUTBLTEACUT / BLTE
Capitalization2.75M1.94B0%
EBITDA-1.74M-35.42M5%
Gain YTD-61.30737.617-163%
P/E RatioN/AN/A-
Revenue00-
Total Cash9.37KN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
ACUTBLTE
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 16 days ago
74%
Bullish Trend 16 days ago
75%
Declines
ODDS (%)
Bearish Trend 9 days ago
82%
Bearish Trend 1 day ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
69%
View a ticker or compare two or three
Ad is loading...
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BLTE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VEVYX47.12N/A
N/A
Victory Sycamore Established Value Y
QFVOX22.78-0.13
-0.57%
Pear Tree Polaris Foreign Value Ord
DDICX14.76-0.28
-1.86%
Delaware Wealth Builder C
GPEIX12.01-0.24
-1.96%
Grandeur Peak Emerg Mkts Opps Instl
LUSIX11.46-0.43
-3.62%
Lazard US Systematic Small Cap Eq Ins

ACUT and

Correlation & Price change

A.I.dvisor tells us that ACUT and KMSTF have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACUT and KMSTF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACUT
1D Price
Change %
ACUT100%
N/A
KMSTF - ACUT
28%
Poorly correlated
N/A
MOLN - ACUT
21%
Poorly correlated
+0.95%
PHGE - ACUT
20%
Poorly correlated
-6.60%
TELIF - ACUT
11%
Poorly correlated
-5.43%
BLTE - ACUT
11%
Poorly correlated
-0.16%
More

BLTE and

Correlation & Price change

A.I.dvisor tells us that BLTE and ALEC have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BLTE and ALEC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLTE
1D Price
Change %
BLTE100%
-0.16%
ALEC - BLTE
24%
Poorly correlated
-5.82%
ACOG - BLTE
24%
Poorly correlated
-7.53%
SAGE - BLTE
23%
Poorly correlated
-4.55%
TVTX - BLTE
23%
Poorly correlated
-1.63%
APLS - BLTE
22%
Poorly correlated
-1.48%
More